ImmVira Presents Promising Phase I Results for Oncolytic HSV Therapy MVR-C5252 in Recurrent Malignant Glioma at AACR 2025

From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-...

April 28, 2025 | Monday | News
Jazz Pharmaceuticals’ Zanidatamab Receives Positive CHMP Opinion for HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...

April 28, 2025 | Monday | News
Merck’s KEYTRUDA Significantly Improves Event-Free Survival in Resectable Head and Neck Cancer in Phase 3 KEYNOTE-689 Trial

Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizu...

April 28, 2025 | Monday | News
Pfizer’s Sasanlimab Plus BCG Significantly Extends Event-Free Survival in High-Risk NMIBC Patients in Phase 3 Trial

Pfizer Inc. announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...

April 28, 2025 | Monday | News
Cordis Unveils Groundbreaking Long-Term Data Supporting SELUTION SLR™ DEB in Treating Complex PAD

 Cordis, a global leader in interventional cardiovascular and endovascular technologies, announced new data from two major peripheral studies evaluati...

April 25, 2025 | Friday | News
Insmed Announces Landmark Phase 3 ASPEN Study Results Demonstrating Brensocatib’s Breakthrough Potential in Bronchiectasis

Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patie...

April 24, 2025 | Thursday | News
Adcentrx Therapeutics to Present First Clinical Data for ADC Candidate ADRX-0706 at 2025 ASCO Annual Meeting

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...

April 24, 2025 | Thursday | News
Boehringer Ingelheim and Tessellate Bio Forge €500M Deal to Develop First-in-Class Oral Cancer Therapies Targeting ALT-Dependent Tumors

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...

April 23, 2025 | Wednesday | News
Ascletis Reports Positive Phase Ib Results for Oral GLP-1R Agonist ASC30 in Obesity, Supporting Phase IIa Advancement

 Ascletis Pharma Inc.  announces  positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...

April 23, 2025 | Wednesday | News
Bristol Myers Squibb Reports Mixed Phase 3 ARISE Results for Cobenfy in Schizophrenia

 Bristol Myers Squibb  announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline...

April 23, 2025 | Wednesday | News
DESTINY-Breast09 Trial Shows Enhertu + Pertuzumab Significantly Improves PFS in 1st-Line HER2-Positive Metastatic Breast Cancer

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in co...

April 23, 2025 | Wednesday | News
Roche to Invest $50 Billion in U.S. Operations, Boosting Manufacturing, R&D, and Job Creation

Roche  announced  that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...

April 23, 2025 | Wednesday | News
HUTCHMED Completes Enrollment in Phase II Registration Trial of Savolitinib for MET-Amplified Gastric Cancer

HUTCHMED (China) Limited (“HUTCHMED”)  announces that it has completed enrollment of the registration phase of its Phase II trial of savol...

April 22, 2025 | Tuesday | News
Leukemia & Lymphoma Society Launches Groundbreaking Pediatric Subtrial in Global PedAL Master Clinical Trial

The Leukemia & Lymphoma Society (LLS) announced the first pediatric patient has received treatment in a new subtrial of its Pediatric Ac...

April 22, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close